The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

被引：41

作者：

Holubec, Lubos ^{[1
,4
]}

Polivka, Jiri, Jr. ^{[1
,2
]}

Safanda, Martin ^{[4
]}

Karas, Michal ^{[3
]}

Liska, Vaclav ^{[1
]}

机构：

[1] Charles Univ Prague, Biomed Ctr, Fac Med Plzen, Plzen, Czech Republic

[2] Charles Univ Prague, Dept Histol & Embryol, Fac Med Plzen, Plzen, Czech Republic

[3] Charles Univ Prague, Dept Hematol & Oncol, Fac Med Plzen, Plzen, Czech Republic

[4] Na Homolce Hosp, Dept Clin Oncol, Prague, Czech Republic

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 09期

关键词：

Colorectal cancer; cetuximab; immune response; targeted therapy; immunomodulation; review; GAMMA RECEPTOR POLYMORPHISMS; CHECKPOINT INHIBITORS; MONOCLONAL-ANTIBODIES; THERAPY; EGFR; IMMUNOTHERAPY; PANITUMUMAB; SURVIVAL; MICROENVIRONMENT; CYTOTOXICITY;

D O I：

10.21873/anticanres.10985

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.

引用

页码：4421 / 4426

页数：6

共 45 条

[1] The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies [J].

Ahmadzadeh, Vahideh ;

Tofigh, Roghaye ;

Farajnia, Safar ;

Pouladi, Nasser .

INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2016, 35 (02) :136-155

[2]

[Anonymous], ANN ONCOL

[3] Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety [J].

Azoury, Said C. ;

Straughan, David M. ;

Shukla, Vivek .

CURRENT CANCER DRUG TARGETS, 2015, 15 (06) :452-462

[4] Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer [J].

Bakema, Jantine E. ;

van Egmond, Marjolein .

FC RECEPTORS, 2014, 382 :373-392

[5]

Brower V., 2015, J Natl Cancer Inst, V107

[6] Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity [J].

Derer, Stefanie ;

Glorius, Pia ;

Schlaeth, Martin ;

Lohse, Stefan ;

Klausz, Katja ;

Muchhal, Umesh ;

Desjarlais, John R. ;

Humpe, Andreas ;

Valerius, Thomas ;

Peipp, Matthias .

MABS, 2014, 6 (02) :409-421

[7] Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients [J].

Deschoolmeester, Vanessa ;

Baay, Marc ;

Van Marck, Eric ;

Weyler, Joost ;

Vermeulen, Peter ;

Lardon, Filip ;

Vermorken, Jan B. .

BMC IMMUNOLOGY, 2010, 11

[8] Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development [J].

Gancz, Dana ;

Fishelson, Zvi .

MOLECULAR IMMUNOLOGY, 2009, 46 (14) :2794-2800

[9] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[10]

Holubec L, 2012, ANTICANCER RES, V32, P4007

← 1 2 3 4 5 →